Dr. Marashi provides and overview on CLL management highlighting promising future treatment approaches and talking about combination therapy
Dr. Mahmoud Marashi, UAE
Dr. Mahmoud Marashi, Head of Hematology Unit Consultant Physician/Clinical Haematologist Rashid Hospital, Dubai, United Arab Emirates discusses the evolvement of CLL management. Dr. Mahmoud Marashi initially started with the basics of CLL/SLL. He gives an impact of TP53 aberrations in CLL patients prior to novel targeted therapies. Dr. Mahmoud Marashi also gives an overview for somatic hyper-mutation of Ig-gene. He provides a brief regarding current therapies in CLL/SLL, BTK inhibitors in treatment -Naïve CLL and in R/R CLL by giving few trial data along with few potential AEs. He also discusses about BCL-2 inhibitor. He highlighted the impact of combination therapy in the treatment and as a promising agent in the future.
Explore more videos
Translating Data Into Clinical Practice
Dr. Abdulkareem Algarni, KSA
Critical Evaluation of BTKis in CLL
Dr. George Follows, UK
CLL Management Inside the Clinic
Dr. Hani Yousif Osman , UAE